Sangamo BioSciences Changes Name to Sangamo Therapeutics

Sangamo Therapeutics said Friday that it has changed its corporate name from Sangamo Biosciences to Sangamo Therapeutics. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the same ticker symbol “SGMO.”

“Our new name, Sangamo Therapeutics, reflects our commitment to advance our groundbreaking science into the clinic for the development of transformative therapies for serious, genetically tractable diseases,” said CEO Sandy Macrae.

The company expects to enroll four clinical trials in 2017 for its lead programs developing new therapies for patients with hemophilia A and B and lysosomal storage disorders MPS 1 and 2.

Leave a Comment